SAN DIEGO--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the ...

In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable ...

Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for ...

Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...

A recent study found that the ranibizumab port delivery system (PDS) has cost-saving potential compared with regular ranibizumab or aflibercept injections for age-related macular degeneration if used ...

Lucentis (ranibizumab) is a brand-name eye injection that’s prescribed for certain eye conditions in adults. As with other drugs, Lucentis can cause side effects, such as eye pain or irritation. More ...

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar ...

- COLUMBUS AMD trial was published in the journal Ophthalmology and demonstrated the clinical equivalence of CIMERLI™ to Lucentis® with a comparable safety and immunogenicity profile - REDWOOD CITY, ...